AMBI sold two unapproved hydroquinone skin-bleaching fade creams with unlawful labeling, FDA says.
What happened
FDA reviewed AMBI’s product labels and its website, where the two fade creams were offered for purchase; the letter does not describe an inspection. FDA found claims that the products are skin bleaching agents containing 2% hydroquinone and that they fade dark spots. FDA says no approved new drug application is in effect, so the products are unapproved and misbranded (unlawfully labeled or marketed).
What FDA found
The two fade creams are new drugs sold without an FDA-approved new drug application.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The products are misbranded because they are nonprescription drugs not covered by an approved application and do not meet section 505G requirements.
section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)FDA treats skin bleaching drugs containing hydroquinone as not generally recognized as safe and effective under its proposed rule, so they are deemed new drugs.
section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4)Introducing these products into interstate commerce is prohibited.
sections 301(d) and 301(a) of the FD&C Act, 21 U.S.C. 331(d) and 331(a)
What FDA wants
FDA tells AMBI to investigate and correct the violations, prevent recurrence, and respond in writing within 15 working days with actions taken or reasoning and a completion schedule if more time is needed.
Who should pay attention
- retailers and websites selling AMBI fade creams
- brands selling hydroquinone skin-bleaching products
- companies marketing OTC drugs without an approved application
This is a summary. Read the original letter on fda.gov.